- Exchange: Toronto
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Snapshot for QLT Inc (QLT)
| Open: | 8.1500 | Day's Range: | 8.1500 - 8.2200 | Volume: | 10,297 |
|---|---|---|---|---|---|
| Previous Close: | 8.1500 | 52wk Range: | 6.8100 - 9.2000 | 1-Yr Rtn: | +18.92% |
Key Statistics for QLT
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPTSX | - |
| Earnings Per Share (USD) (ttm) | -0.7700 |
| Est. EPS (USD) (12/2013) | -0.5050 |
| Est. PEG Ratio | - |
| Market Cap (M CAD) | 412.83 |
| Shares Outstanding (M) | 50.53 |
| 30 Day Average Volume | 12,634 |
| Price/Book (mrq) | 1.0698 |
| Price/Sale (ttm) | 48.5082 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend (USD) | 3.9500 |
| Last Dividend | 06/20/2013 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for QLT
Company Profile & Key Executives for QLT
QLT Inc. develops and commercializes pharmaceutical products for use in photodynamic therapy, the use of light activated drugs to treat disease. The Company's lead drug, Visudyne, is marketed by Novartis AG, and is used in the treatment of the wet form of age-related macular degeneration.
| Jason M AryehChairman | Sukhi JagpalChief Financial Officer |
| Alexander R LussowSenior VP:Business Development | Sushanta MallickSenior VP:Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
QLT News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page